What question did this study set out to answer?

To report a case of B-cell acute lymphoblastic leukemia (B-ALL) as a secondary malignancy following lenalidomide treatment in a multiple myeloma patient.

August 11, 2026Journal of Medical Case ReportsOpen Access

Lenalidomide-associated B-cell acute lymphoblastic leukemia in a multiple myeloma patient: a case report

View Full Paper

Ask AI

Bookmark

Authors

IZIbrahim ZahidWestern Michigan University AMAli Abbas MankaniCivil Hospital Karachi MKMatthew KellyWestern Michigan University

Discussion

Member takes

Implication

Case report reveals B-cell acute lymphoblastic leukemia in multiple myeloma patient, suggesting lenalidomide's risks.

Key Points

To report a case of B-cell acute lymphoblastic leukemia (B-ALL) as a secondary malignancy following lenalidomide treatment in a multiple myeloma patient.
Documented treatment history of a 73-year-old male with multiple myeloma and symptoms during follow-up.
Conducted a bone marrow biopsy confirming B-ALL with flow cytometry.
Implemented R-hyper-CVAD chemotherapy and monitored patient outcomes.
Patient diagnosed with B-ALL after lenalidomide therapy presented with thrombocytopenia.
Achieved complete remission after R-hyper-CVAD chemotherapy.
Patient opted for surveillance only, prioritizing quality of life.

Cite This Study

Zahid et al. (2026) studied this question.

synapsesocial.com/papers/6a7ace0a3401087f2249dbc9 https://doi.org/10.1186/s13256-026-06453-6

View Full Paper

Ask AI

Bookmark

Lenalidomide-associated B-cell acute lymphoblastic leukemia in a multiple myeloma patient: a case report

Discussion

Member takes

Implication

Key Points

Cite This Study

Lenalidomide-associated B-cell acute lymphoblastic leukemia in a multiple myeloma patient: a case report

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider